...We Welcome You to the Zenith Epigenetics Hub withIn The AGORACOM COMMUNITY!

Zenith's BET Inhibitor ZEN-3694 is Currently Being Evaluated in Multiple Oncology Clinical Trials

Free
Message: New paper on interplay/synergy of BET inhibitors and PD-L1 inhibition
Reply New Message
Prev Message Back To Forum Threaded View Next Message

Thank you Bear for you explanation, 

Can we however say that to this point  Zen3694 does not have any safety issues to warrant a stoppage of the trial, , which is a postive,     

3 Recommendations
Reply New Message
Prev Message Back To Forum Threaded View Next Message
Share
Share
New Message
Please login to post a reply